Teva launches first DTC for Austedo into competitive tardive dyskinesia 2-drug market

Teva's first DTC campaign for tardive dyskinesia (TD) drug Austedo launches into a suddenly competitive TV ad space for the rare condition. It joins Neurocrine Biosciences' Ingrezza campaign that began in April.